Literature DB >> 15355565

Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis.

Elisabeth J Smith1, Anthony McEvoy, David G Little, Paul A Baldock, John A Eisman, Edith M Gardiner.   

Abstract

UNLABELLED: Bisphosphonates induce major increases in strength of callus in distraction osteogenesis in the short term. Poor understanding of the underlying mechanism, however, raises concerns about long-term consequences. In this long-term study in 32 rabbits, zoledronic acid transiently increased trabeculae by delayed temporal progression of endochondral bone remodeling but did not prevent radiographic completion of bone repair.
INTRODUCTION: We hypothesized that bisphosphonate inhibition of osteoclast-mediated resorption would retain bone during repair, producing a larger callus in the short term. However, if remodeling was not restored, completion of the bone repair process in the long term could be jeopardized.
MATERIALS AND METHODS: Juvenile rabbits underwent right tibial osteotomy and 2 weeks of distraction, followed by a period of consolidation. Animals received saline (controls) or zoledronic acid (ZA; 0.1 mg/kg at surgery and again 2 weeks later), and distracted tibias were examined by radiograph, DXA, histology, and histomorphometry at 2, 4, 6, 18, and 44 weeks after surgery.
RESULTS: Regenerated bone in ZA-treated animals was denser than controls on radiographs at 6 weeks and had more distinct radiodense trabeculae and retention of original cortices at 18 weeks. By 44 weeks, controls and ZA-treated animals were radiographically healed and indistinguishable. Regenerate BMD and BMC increased between 2 and 4 weeks in all animals, with a greater effect in ZA. At 6 weeks, BMD and BMC in ZA-treated animals were 1.6- and 2-fold greater, respectively, than controls (p < 0.01). From 6 to 44 weeks, the control values gradually increased and approached the ZA-treated values. Regenerate bone volume and trabecular number by histomorphometry were from 1.6- to 2-fold greater in ZA-treated animals at 6 and 18 weeks (p < 0.05). Endochondral cartilaginous matrix volume was up to 2.4-fold greater in ZA-treated animals at 2 and 4 weeks (p < 0.05). TRACP+ cells in ZA-treated animals were larger with more nuclei. Mineral apposition rate and osteoblast number and surface were lower in ZA-treated animals at 6 weeks (p < 0.01) but not at later times.
CONCLUSIONS: Disruption of TRACP+ cell function by ZA during bone regeneration seems to lead to an accretion of cancellous bone built on a larger endochondral cartilaginous matrix and increased bone mass, consistent with reported increases in short-term callus strength. This increase in bone mass, caused by a delay in remodeling, provided a transient advantage without preventing radiographic completion of the bone repair process in the long term. Noncontinuous treatment with nitrogen-containing bisphosphonates thus can have short-term beneficial effects without preventing long-term bone repair.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355565     DOI: 10.1359/JBMR.040709

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  6 in total

1.  Pulsed electromagnetic fields preserve bone architecture and mechanical properties and stimulate porous implant osseointegration by promoting bone anabolism in type 1 diabetic rabbits.

Authors:  J Cai; W Li; T Sun; X Li; E Luo; D Jing
Journal:  Osteoporos Int       Date:  2018-03-09       Impact factor: 4.507

2.  Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.

Authors:  A L Boskey; L Spevak; R S Weinstein
Journal:  Osteoporos Int       Date:  2008-09-04       Impact factor: 4.507

3.  Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.

Authors:  J A Meganck; D L Begun; J D McElderry; A Swick; K M Kozloff; S A Goldstein; M D Morris; J C Marini; M S Caird
Journal:  Bone       Date:  2013-06-14       Impact factor: 4.398

4.  Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats.

Authors:  Jörgen Astrand; Anna Kajsa Harding; Per Aspenberg; Magnus Tägil
Journal:  BMC Musculoskelet Disord       Date:  2006-08-04       Impact factor: 2.362

5.  Indirect osteoblast differentiation by liposomal clodronate.

Authors:  Emi Okada; Hidemi Nakata; Maiko Yamamoto; Shohei Kasugai; Shinji Kuroda
Journal:  J Cell Mol Med       Date:  2017-10-24       Impact factor: 5.310

6.  Influence of bisphosphonate treatment on medullary macrophages and osteoclasts: an experimental study.

Authors:  Natalia Daniela Escudero; Patricia Mónica Mandalunis
Journal:  Bone Marrow Res       Date:  2012-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.